|
|
 |
|
Viewing report
|
|
|
|
Innovative Agents in Lung and Colorectal Cancer - Another Step Nearer the Revolution?
Datamonitor, April 2004, Pages: 63
Treatment for cancer, traditionally dominated by cytotoxic and hormonal therapies, is currently being revolutionized by the emergence of innovative, targeted therapies with the potential to offer improved efficacy and reduced toxicity.
One such class of innovative agents is the epidermal growth factor receptor (EGFR) inhibitor class, which is being investigated for NSCLC and colorectal cancer.
Scope of Report:
- Overview of EGFR inhibitors and their role in the NSCLC market
- Strategy for maximizing the potential of EGFR inhibitors such as Iressa, Tarceva and Erbitux
Report Highlights:
ImClone/BMS/Merck KGaA’s Erbitux (cetuximab), a monoclonal antibody EGFR inhibitor, may potentially succeed where small molecule EGFR inhibitors such as Iressa have failed by gaining approval for second-line NSCLC therapy. An early clinical trial has indicated a significant promise but the results need to be validated in Phase III trials.
Reasons to Purchase Report:
- Assess opportunities and risks in the innovatives market by understanding the potential of EGFR inhibitors in the NSCLC market
- Evaluate the impact of market entry of pipeline innovative agents by redefining the marketing strategy for EGFR inhibitors
Scope of Report:
- Analysis of key findings of INTACT I and II trials for Iressa (gefitinib)
- Key events in the lung and colorectal cancer markets in the first quarter of 2004
Report Highlights:
Unless clinical trials finally enable uptake in to adjuvant, first- and second-line markets, EGFR inhibitors will be limited to third-line use in NSCLC.
EGFR inhibition with Erbitux clearly invokes a highly individualized response, which has significant diagnostic and clinical trial design implications. If the true potential of EGFR inhibitors, and other developmental targeted agents, is to be realized, clinical trial endpoints and patient inclusion criteria will have to adapt over coming years.
Reasons to Purchase Report:
- Determine the key future trends of EGFR inhibitors in other indications such as colorectal cancer
Customers who bought this item also bought
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Pipeline Insight: Colorectal Cancer - Avastin and Erbitux Pave The Way For Pipeline Targeted Therapies
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Pipeline Insight: Molecular Targeted Cancer Therapies - More Pipeline Activity, Less Product Differentiation
Pipeline Insight: Non-Small Cell Lung Cancer - Pipeline Set To Offer Only Modest Improvements
Innovative and Targeted Cancer Therapies: Key Technologies, New Applications and Leading Players
Cancer Drug Discoveries: What the Future Holds: Colorectal Cancer Chapter
Targeted Cancer Therapies: Innovative Drugs And Their Impact On The Future Of Oncology
Angiogenesis Inhibitors: An Update - Can Iressa and Thalomid Rejuvenate the Angiogenesis Inhibitor Class?
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
Non-Small Cell Lung Cancer - Avastin to Lead the Market
Cancer Therapies - Global Strategic Business Report
|
|
|
|
